8-K: ORIC Pharmaceuticals Shareholders Elect Directors and Ratify Auditor at Annual Meeting

ORIC Pharmaceuticals, Inc. successfully held its annual meeting of stockholders on June 11, 2025, with shareholders electing two Class II directors and ratifying KPMG LLP as its independent registered public accounting firm.

Summary

• ORIC Pharmaceuticals, Inc. conducted its annual meeting of stockholders on June 11, 2025.
• As of the record date, April 16, 2025, there were 71,085,080 shares of common stock outstanding.
• A significant majority of shares, 58,306,933 (82.02% of outstanding common stock), were represented at the meeting in person or by proxy.
• Shareholders elected Steven L. Hoerter and Angie You, Ph.D., as Class II directors; both will serve until the company's 2028 annual meeting.
• The appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified by a substantial majority of votes.

Sentiment

Score: 7

Explanation: The document reports routine and successful outcomes of an annual shareholder meeting, indicating stable corporate governance without any negative surprises. The high voter turnout and approval rates for all proposals are positive indicators of shareholder confidence in the current management and governance structure.

Positives

• High shareholder participation with 82.02% of outstanding shares represented at the meeting.
• Both nominated Class II directors, Steven L. Hoerter and Angie You, Ph.D., were successfully elected with strong support.
• The appointment of KPMG LLP as the independent registered public accounting firm was overwhelmingly ratified, indicating confidence in the company's financial oversight.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of annual meeting results for a publicly traded pharmaceutical company, reflecting routine corporate governance practices. It does not contain information that directly relates to broader industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: Confirmed board leadership and independent auditor, providing stability and oversight.
• Management: Received shareholder endorsement for the proposed directors and auditor.

Next Steps

• Elected Class II directors, Steven L. Hoerter and Angie You, Ph.D., will hold office until the 2028 annual meeting of stockholders.
• KPMG LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

ORIC Pharmaceuticals, SEC Filing, 8-K, Annual Meeting, Shareholder Vote, Director Election, Auditor Ratification, Corporate Governance, Biotechnology, Pharmaceuticals